1. Academic Validation
  2. Synthesis and antitumor evaluation of bis aza-anthracene-9,10-diones and bis aza-anthrapyrazole-6-ones

Synthesis and antitumor evaluation of bis aza-anthracene-9,10-diones and bis aza-anthrapyrazole-6-ones

  • J Med Chem. 2008 Feb 28;51(4):997-1006. doi: 10.1021/jm7013937.
Ippolito Antonini 1 Giorgio Santoni Roberta Lucciarini Consuelo Amantini Diego Dal Ben Rosaria Volpini Gloria Cristalli
Affiliations

Affiliation

  • 1 Department of Chemical Sciences, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy. ippolito.antonini@unicam.it
Abstract

The good results obtained as potential antitumor drugs with aza-anthracenediones and aza-anthrapyrazoles, e.g. pixantrone, 1a, and 1b (Chart 1), prompted us to design and synthesize a series of symmetrical bis derivatives, compounds 7-10 (Chart 1). These compounds are dimers of different aza-anthracenedione and aza-anthrapyrazolone monomers connected by the linker found to be the most appropriate among potential bis intercalators synthesized by us. The DNA-binding properties of bis derivatives 7 and 8 have been examined using fluorometric techniques: these target compounds are excellent DNA ligands, with a clear binding site preference for AT-rich duplexes. In vitro cytotoxic activity of all target compounds 7-10 and of reference compound pixantrone toward human Cancer adenocarcinoma cell line HT29 is also described. Two selected compounds have been investigated for their capacity of inducing early Apoptosis.

Figures